ITherX Repurposes Kemia Drug

3/24/11Follow @bvbigelow

San Diego’s ITherX Pharmaceuticals has begun enrolling liver transplant patients in an early stage hepatitis C trial that seeks to repurpose a drug that was initially under development for treating inflammation. ITherX, with backing from Easton Capital and others, acquired the experimental compound from San Diego-based Kemia in 2009 for $75,000, according to VentureWire. In a proof-of-concept trial that began earlier this month, ITherX says it is testing whether the compound can help prevent the hepatitis C virus from infecting the transplanted liver. Kemia, which discovered the molecule, halted development after the drug failed a mid-stage trial for rheumatoid arthritis.

Bruce V. Bigelow is the editor of Xconomy San Diego. You can e-mail him at bbigelow@xconomy.com or call (619) 669-8788 Follow @bvbigelow

By posting a comment, you agree to our terms and conditions.